Background: Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) comprises the administration of heated, humidified, and blended air/oxygen mixtures via nasal cannula at rates of !2 litres kg À1 min À1 . The aim of this
Editor's key points
Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) extends time to hypoxaemia in apnoeic adult patients, but it is not known whether THRIVE is effective in children as well. In apnoeic children, compared with conventional administration of 100% oxygen, THRIVE with 100% oxygen was not effective in extending the time to hypoxaemia.
High-flow nasal cannula therapy (HFNCT) is defined as the administration of a heated, humidified and blended air/oxygen mixture via nasal cannula at rates of !2 litres kg À1 min À1 . 1 HFNCT serves different purposes in different age groups: in preterm infants, it is used in respiratory distress of different aetiologies 2 and for respiratory support after extubation 3 ; in infants it is used for the treatment of bronchiolitis 4 and other respiratory illnesses. Its use in adults focuses on hypoxaemic respiratory failure in intensive care patients 2 and on improving oxygenation during intubation. 5 Humidified high-flow oxygen extends the safe apnoea time of adults undergoing hypopharyngeal or laryngotracheal surgery 6 and of children undergoing laryngeal surgery. 7 Apart from extending the safe apnoea period, HFNCT appears to reduce the accumulation of CO 2 in adults. In 2015, 'transnasal humidified rapid-insufflation ventilatory exchange' (THRIVE) was therefore introduced. 6 Recently, THRIVE was also reported to prolong the safe apnoea time during intubation in children. 8 Compared with adults, infants and neonates exhibit reduced apnoea tolerance as a result of increased oxygen consumption, reduced functional residual capacity, 9 and greater closing capacity which precipitates airway collapse. 10 This leads to higher rates and faster onset of hypoxaemia after cessation of spontaneous or assisted ventilation during the induction of general anaesthesia. Without proper preoxygenation, apnoea leads to hypoxaemia within seconds in 1-yrold infants. 11, 12 Even when children can be ventilated easily with a face mask, 13 airway complications are more common than in adults. As a result, complications arising from unexpected difficulty in paediatric airway management may lead to detrimental outcomes. 14 Approaches that reduce desaturation and maintain oxygenation during prolonged intubation attempts or during prolonged airway management are needed. The aim of this randomized controlled study was to evaluate whether the safe apnoea time can be extended by using transnasal humidified high-flow oxygen in children with two different oxygen concentrations and compared with low-flow nasal cannula oxygen. The second aim was to investigate the rate of increase of transcutaneous (tc) CO 2 during apnoea.
Methods
With approval from the Cantonal Ethics Committee of Bern (reference number KEK-BE 2016-01516) and after registration at ClinicalTrials.gov (NCT02979067), we obtained written informed consent from the parents or legal guardians of all patients before study enrolment.
This single centre, prospective, single-blinded, randomised controlled trial was conducted at Bern University Hospital, Bern, Switzerland between December 2016 and May 2017. Inclusion criteria were children weighing 10.0e20.0 kg with an ASA physical status of I or II, requiring elective surgery under general anaesthesia. Exclusion criteria were known or suspected difficult intubation, known or anticipated difficult bagmask ventilation, oxygen dependence, congenital heart or lung disease, obesity (BMI >30 kg m À2 ), contraindication for neuromuscular block, upper airway obstruction, risk of aspiration, and parents not speaking or understanding German. Eligible children were identified from theatre lists and recruited during preadmission clinic.
Patients were randomly assigned to one of three study groups using computer-generated randomisation (www. randomization.com) and sealed opaque envelopes with stratification according to weight: (10.0e15.0 kg and 15.1e20.0 kg). Randomization was performed after induction of anaesthesia once easy face-mask ventilation had been confirmed. Due to the clinically obvious oxygen administration modalities, study personnel in theatres could not be blinded, but patients and parents were blinded to group allocation.
All patients received premedication consisting of 0. 5 . Anaesthetic depth was assessed with Narcotrend™ (Narcotrend, Hannover, Germany), maintaining values below 60. After induction all patients were paralysed with 0.2 mg kg À1 of cisatracurium.
Neuromuscular block was assessed by train-of-four (TOF) monitoring using TOF-Watch (Organon Ltd, Dublin, Ireland). TOF value before apnoea was 0. After induction, bag-mask ventilation with 100% oxygen and flow rates of 6e8 litres min À1 were carried out until the expired oxygen concentration was >90%, SpO 2 was 100%, and tcCO 2 was 30e40 mmHg. Once this was reached, bag-mask ventilation was halted. Apnoea was initiated according to randomization to one of three allocated treatments:
2) THRIVE 100% oxygen at 2.0 litres kg À1 min À1 (2.0L100%),
3) THRIVE 30% oxygen at 2.0 litres kg À1 min À1 (2.0L30%).
The gas mixture for THRIVE was delivered using the Optiflow™ system (Fisher&Paykel™, Auckland, New Zealand), which is composed of a humidifier base, a heater wire, a temperature probe, an oxygen/air blender, and a circuit that includes a humidifier chamber, tubing system, and a pressure relief valve for the paediatric circuit. In children weighing 10.0e12.4 kg, a paediatric nasal cannula with tubing system RT330 was used, and for children weighing 12.5e20.0 kg, the Optiflow adult nasal cannula size 'small' with tubing system RT202 was used. Low-flow oxygen was delivered using a nasal cannula (O2Star™; Dr€ ager, Lü beck, Germany). Continuous jaw thrust and the insertion of an oropharyngeal airway (Guedel airway; Intersurgical ® , Wokingham, UK) ensured airway patency.
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Apnoea time was measured from the cessation of bagmask ventilation until one of three predefined termination criteria occurred. Termination criteria were: 1) SpO 2 reduction to 95%; 2) tcCO 2 reaching 65 mmHg (8.7 kPa); or 3) apnoea time reaching 10 min. If one of these criteria was met, apnoea was terminated and bag-mask ventilation was re-applied, and the study observation was concluded. Patients were intubated and managed according to the attending anaesthesiologist. After intubation a manual recruitment manoeuvre was performed in every patient.
During apnoea transcutaneous CO 2 and O 2 concentrations were recorded every 10 s and standard non-invasive anaesthesia monitoring. Chest ultrasound was performed before and after apnoea to rule out a pneumothorax (Sonosite MTurbo; FUJIFILM SonoSite Inc, Bothell, WA, USA). Continuous gastric ultrasound assessed whether gases had entered the stomach from the time of induction of anaesthesia until the end of apnoea. The gastric antrum was identified in crosssection on a sagittal or sagittal oblique plane defined by the aorta. 15 Before the patients left the post anaesthesia care unit parents were asked about any postoperative side effects such as postoperative nausea and vomiting, stridor, coughing, laryngospasm, bronchospasm, or pain.
Statistics
Primary outcome was apnoea time until one of the termination criteria was reached. Secondary outcomes were the rate of increase of tcCO 2 concentrations during apnoea and the occurrence of side effects secondary to high-flow oxygen/air administration. The hypothesis stated that THRIVE with 100% oxygen would prolong apnoea compared with low-flow 100% oxygen by at least 1 min. The sample size was based on the preliminary clinical observation of apnoea time and extrapolated from previously published data. 7 We calculated that the detection of an effect 
Results
Sixty children were included in the study. Patient characteristics are summarised in Table 1 . Two patients had to be excluded from the low-flow group (0.2L100%): one patient had a TOF of 2 and diaphragmatic respiratory movements which constituted a protocol violation and the other patient exhibited technical problems with the tcCO 2 monitor, leading to incorrect tcCO 2 measurements. The complete datasets of 58 patients were analysed (Fig. 1) .
Median apnoea time was 6.9 (5.7e7. Fig. 2 ). The posthoc analysis found no difference in apnoea time between the lowflow 0.2L100% group and THRIVE 2.0L100% group (P¼0.147), but THRIVE 2.0L30% revealed a significantly shorter apnoea time compared with both 100% O 2 groups (both P<0.001). Table 3 shows the distribution of the termination criteria. In all 30% oxygen THRIVE patients, apnoea was terminated because SpO 2 concentrations decreased to 95%, whereas this only happened in three patients with low-flow 100% oxygen and in no patients with THRIVE 100% oxygen. With low-flow 100% oxygen, 13 patients reached the termination criterion of 65 mmHg tcCO2, in comparison with 16 with THRIVE 100%. An apnoea time of 10 min terminated the study in two patients with low-flow 100% oxygen and in four patients with THRIVE 100%.
The overall rate of tcCO 2 increase was 0.57 (0.49e0.63) [0.29e8.92] kPa min À1 without differences between the three groups (P¼0.25, Table 2 ). No pneumothorax was found in any of the patients and no patient exhibited gastric air insufflation during the apnoea time as verified by ultrasound imaging.
In the 100% oxygen groups, the heart rate increased by about 10 beats min À1 during apnoea. This was not observed with 30% oxygen during apnoea (Table 1 ). These findings reflect that the duration of apnoea in the low oxygen group was only half as long as in the 100% oxygen groups (Table 2) . Except for this slight increase in heart rate, no further haemodynamic changes or complications such as heart rhythm disturbances or pulmonary hypertensive crises were observed. Whenever one of the termination criteria was met, bagmask ventilation was restarted immediately. Six patients desaturated to 90e94% SpO 2 , 15 to 83e89%, and one to 69% before intubation. With bag-mask ventilation, all patients reached saturations above 95% within 1 min and no complications or desaturations were observed in the recovery area. When comparing the two weight groups (10.0e15.0 vs 15.1e20.0 kg) no difference in termination criteria (Table 4) was found. Apnoea times were the same in both weight groups, and for 100% oxygen low-flow and 100% oxygen THRIVE (P¼0.22 for 15.1e20.0 kg, P¼0.31 for 10.0e15.0 kg). Both low-flow and THRIVE 100% oxygen delivery resulted in significantly longer apnoea times compared with 30% oxygen THRIVE (P<0.01). The overall rate of tcCO 2 
Discussion
This study shows that, during apnoea, supplemental low-flow nasal cannula oxygen (100% at 0.2 litres kg À1 min
À1
) and highflow 100% oxygen (THRIVE) significantly prolong apnoea time compared with high-flow 30% oxygen supplementation in children weighing 10e20 kg. The median difference [95% confidence interval (CI)] between low-flow and THRIVE 100% oxygen was only 50.5 (e17 to 152) s (HodgeseLehmann). The rate of tcCO 2 increase during apnoea was similar with THRIVE and with low-flow oxygen therapy at 0.57 kPa min À1 . However, smaller children showed a more rapid tcCO 2 increase during apnoea. These results are somewhat surprising, as we expected THRIVE to be superior to low-flow techniques in both oxygenation and elimination of CO 2 , because recent data from adults reported not only substantially prolonged apnoea time, but also slower CO 2 increase with THRIVE. 6, 16 It is well known from clinical practice that infants desaturate swiftly in the absence of supplemental oxygen during apnoea. Patel and colleagues 17 reported desaturation during apnoea to 90% after 119 s in infants (7e23 months) and after 160 s in children aged 2e5 yr. Recent studies applying low-flow oxygen prolonged apnoea time. 18 and found that desaturation to a SpO 2 of 90% occurred during intubation in 10e12% compared with 49% in the group without oxygen. The incidence of desaturation was four times higher in the absence of supplemental oxygen. Unfortunately, no data regarding CO 2 increase are available from these studies. In adults, Patel and Nouraei 6 and Gustafson and colleagues 16 reported safe apnoea times of up to 65 min when using THRIVE and lower rates of CO 2 increase compared with other forms of apnoeic oxygenation. 20 THRIVE in adults therefore seems to enable a certain degree of ventilatory exchange, but the exact mechanism of this oxy-ventilation phenomenon is still unclear. It is assumed that THRIVE generates a cascade of vortex flows from the larger to the smaller airways, permitting gas exchange and CO 2 elimination across the alveoloecapillary surface. Using paediatric high-flow nasal cannula oxygenation during general anaesthesia, Humphreys and colleagues 8 showed a substantial prolongation of apnoea time compared with adults. However, in contrast to the THRIVE data in adults, their CO 2 increase was much faster than expected: CO 2 increase of 2.4 mmHg min
(0.32 kPa min À1 ). Consistent with our study, Humphreys and colleagues 8 could not demonstrate a ventilatory CO 2 eliminating effect in children, although they reported an even slower CO 2 increase than our study does. This might be because of the inclusion of children aged up to 10 yr in the study by Humphreys and colleagues, 8 whereas we included children aged only up to 6 yr, who exhibit much higher metabolic demands. Results from intensive care unit studies suggest that low flow rates <1 litres kg À1 min À1 are ineffective for achieving sufficient respiratory support. 21 As our study suggests, a flow rate of >2.0 litres kg À1 min À1 may be necessary to achieve significant respiratory support and CO 2 clearance, 22e24 especially in smaller children. Similarly, the increase in CO 2 concentrations in our study between low-flow and high-flow might be linked to the fact that we did not allow apnoea times to exceed 10 min and limited high-flow to 2 litres kg À1 min À1 . Further studies should investigate whether higher flow rates (up to 4 litres kg À1 min À1 ) provide ventilatory exchange in children.
As expected, the application of high-flow 100% oxygen allowed for an apnoea time of >7 min without desaturation. Interestingly, time to desaturation was not lowered when lowflow 100% oxygen was used. Irrespective of the flow rate, we sensed a more tranquil work environment during both oxygen delivery methods. Prolonged apnoea time and a less stressful work environment may favour increased attention resulting in enhanced patient safety during difficult paediatric airway management.
A possible disadvantage of low-flow oxygen is the lack of humidification. The combination of unheated and dry inspired oxygen has a marked effect on the cilial integrity in the proximal trachea. 25 Mucociliary transport is extremely sensitive to unheated, dry gas inhalation. 26 Damage to the mucociliary layer in dogs occurred within 60 s after exposure to unheated, non-humidified gas. 27 Given this pathophysiological consideration, THRIVE may still be superior to low-flow, unheated, dry oxygen to prolong apnoea. However, for short periods of time or in a setting with limited resources, low-flow 100% oxygen delivery represents a safe alternative to THRIVE. Oxygen concentration may be of greater importance than flow rate. Lower oxygen concentrations (30%) are still used in clinical practice during laser therapy because of the perceived risk of fire during surgical intervention. 28, 29 Our preliminary data showed a promising two-fold increase in safe apnoea time when using high-flow oxygen 30%. 7 However, our current study did not confirm these findings. High-flow with reduced fraction of inspired oxygen was not effective for prolonging apnoea time and should not be considered for clinical anaesthesia practice. Limitations of our study are the single-centre study design, the relatively small sample size limiting generalizability, and our inability to blind the allocation of the three oxygen delivery modalities. As we included only children with healthy lungs (ASA I and II) our findings cannot be extrapolated to sick children. Future THRIVE studies should consider increasing the flow rates, increasing the maximal apnoea times, and including children with systemic diseases. Remaining unanswered research questions include the basic physiology of THRIVE, such as CO 2 elimination in children and more advanced clinical applications, e.g. in tubeless laryngeal surgery.
Reducing risks of perioperative hypoxaemia by using THRIVE to prolong apnoea time during intubation might be one piece in the puzzle of strategies to improve patient safety. THRIVE used in children may contribute to improved patient safety by further optimizing oxygen delivery during preoxygenation 30 and also after extubation.
31
In conclusion, this study has shown that children undergoing general anaesthesia with supplemental 100% oxygen delivered via nasal cannulas using low-flow (0.2 litres kg À1 min À1 ) or high-flow (2.0 litres kg À1 min À1 , THRIVE) exhibit significantly prolonged apnoea time compared with high-flow 30% oxygen. No difference in apnoea time was observed between low-flow and high-flow 100% oxygen. Transcutaneous CO 2 increased substantially faster compared with adult patients, without differences between low-flow and high-flow groups. Smaller children show significantly greater tcCO 2 increase during apnoea compared with older ones. No ventilatory effect was observed with THRIVE at 2.0 litres kg À1 min À1 . The extension of apnoea time, irrespective of oxygen flow, enhances safety in difficult paediatric airway management and may be useful for airway surgery.
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